Literature DB >> 33488899

Unexpected -[18F] fluoro-2-deoxy-D-glucose accumulation in subarachnoid hemorrhage due to an aneurysm rupture.

Hiroyuki Tokue1, Azusa Tokue1, Yoshito Tsushima1.   

Abstract

A 79-year-old Asian man with paranasal cancer underwent 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) to evaluate metastatic lesions. Unexpected FDG accumulation during subarachnoid hemorrhage due to an aneurysm rupture visualized with FDG-PET/CT. It is rare to encounter life-threatening diseases in FDG-PET/CT because FDG-PET/CT is usually scheduled beforehand. However, an immediate response is warranted in unexpected conditions. Physicians who perform FDG-PET/CT should be familiar with life-threatening FDG-PET findings.
© 2021 Published by Elsevier Inc. on behalf of University of Washington.

Entities:  

Keywords:  2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography; Life threatening; Subarachnoid hemorrhage; Unexpected

Year:  2021        PMID: 33488899      PMCID: PMC7809252          DOI: 10.1016/j.radcr.2021.01.009

Source DB:  PubMed          Journal:  Radiol Case Rep        ISSN: 1930-0433


Introduction

Positron emission tomography (PET) with 2-[18F] fluoro-2-deoxy-D-glucose (FDG) is established as one of the main modalities in the diagnosis, staging, and monitoring of neoplastic conditions. Similar to neoplasms, nonneoplastic conditions such as infection, inflammation, and granulomatous diseases appear to present increased glycolysis and are easily visualized through FDG-PET imaging. It is rare to encounter life-threatening diseases in FDG-PET/computed tomography (CT) because FDG-PET/CT is usually scheduled beforehand. However, an immediate response is warranted in unexpected conditions, and FDG-PET/CT is time consuming. Several studies have reported unexpected CT findings in the emergency department, but only few studies have evaluated the unexpected findings in FDG-PET/CT. This study reports the case of unexpected FDG-PET/CT finding in subarachnoid hemorrhage (SAH) due to an aneurysm rupture. This is a rare case of SAH due to aneurysm rupture observed on FDG-PET/CT. Physicians who perform FDG-PET/CT should be familiar with life-threatening FDG-PET findings.

Case report

Paranasal cancer was suspected in a 79-year-old Asian man with a history of meningitis and optic neuritis who presented with mild dementia; however, he was conscious. Metastatic lesions were evaluated using FDG-PET/CT. The patient demonstrated a normal walk in the examination room. Before FDG PET/CT examination, the patient had a rapid blood glucose of 120, normal vital signs, and a blood pressure of 140/70 mm Hg.

FDG PET/CT imaging protocol

The patient fasted for 6h before receiving an intravenous injection of FDG (5 MBq/kg). FDG PET/CT scans were obtained using Biograph 16 (Siemens Medical Solutions; Knoxville, TN) scanners, with a 700-mm Field of view (FOV) and a slice thickness of 3.27mm. The CT was acquired to correct PET transmission using the following parameters: 140kV and 120- 240mAs to produce 128 × 128 matrix images. The patient was scanned in the arms-down position, from head to thigh. Shallow breathing was advised to avoid motion artifacts and minimize misregistration of CT and PET images. Intravenous contrast material was not administered for CT scanning. After the CT scan, the PET data were acquired, and acquisition time was 3min per bed position. CT images were reconstructed using the conventional filtered back-projection method. Axial full width at half-maximum at 1cm from the center of the FOV was 6.3 mm. After more than half a day of examination, the findings were interpreted and SAH was suspected. FDG-PET (Fig. 1A) and FDG-PET/CT (Fig. 1B) revealed FDG accumulation in the bilateral basal cistern with a 5.5 SUVmax. The corresponding plain CT (Fig. 1C) revealed high density in the same regions. Because the patient had gone home after examination, he was immediately called back to the hospital. On his way to the hospital, his consciousness deteriorated, and first aid was administered as soon as he arrived. Contrast-enhanced CT angiography revealed an aneurysm in the right internal carotid artery (Fig. 2); thus, FDG accumulation due to aneurysm rupture. Although treatment was delayed because of the diagnosis of SAH, the patient was saved by a clipping operation.
Fig. 1

Subarachnoid hemorrhage in a 79-year-old man. FDG-PET (A) and FDG-PET/CT fusion (B) images showing FDG accumulation in the bilateral basal cistern. The corresponding plain CT (C) shows high density in the same regions. CT, computed tomography; FDG-PET, fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.

Fig. 2

3D-CT angiography revealed an aneurysm in the right internal carotid artery. CT, computed tomography.

Subarachnoid hemorrhage in a 79-year-old man. FDG-PET (A) and FDG-PET/CT fusion (B) images showing FDG accumulation in the bilateral basal cistern. The corresponding plain CT (C) shows high density in the same regions. CT, computed tomography; FDG-PET, fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. 3D-CT angiography revealed an aneurysm in the right internal carotid artery. CT, computed tomography.

Discussion

SAH is a life-threatening condition with a 40% mortality risk. SAH progression presents several symptoms; the main symptom is a sudden severe headache that is more intense at the base of the skull and is often described as the worst headache ever experienced by a person. Approximately one-third of individuals experience no other symptoms besides this characteristic headache, and approximately 1 in 10 individuals who seek medical care with this symptom is later diagnosed with SAH [1]. In the case presented here, diagnosis was delayed due to unexpected findings in FDG-PET/CT, and the patient did not have any symptoms and or undergo a scheduled FDG-PET/CT. A previous study has noted that 0.35% of patients with tumors had unexpected findings on FDG-PET/CT, with pneumothorax as the most unexpected finding [2]. FDG-PET/CT data acquisition and diagnosis is time consuming, and immediate interventions may be needed in emergency cases. In a previously reported case of SAH visualized on FDG-PET images in the patient with hypoglycemia [3], diffusely reduced FDG uptake in the cerebral and cerebellar cortex improved the observation of high FDG accumulation in the subarachnoid space. However, our case of unexpected SAH was visualized through FDG-PET despite normal blood glucose levels and normal FDG accumulation in the cerebral and cerebellar cortex. To our knowledge, the present case may be the first report on FGD-PET/CT findings of SAH caused by aneurysm rupture. CT is generally completed first during FDG-PET/CT examinations. Hence, CT images should be evaluated as soon as it is available during FDG-PET data acquisition is proceedings. In the case presented here, FDG may have accumulated in the subarachnoid space due to intracranial extravasation of FDG through the ruptured aneurysm. In conclusion, it is rare to observe life-threatening conditions on FDG-PET/CT. However, the early diagnosis of life-threatening conditions influences prognosis. Physicians who perform FDG-PET/CT should be familiar with FDG-PET/CT imaging findings of SAH due to an aneurysm rupture.
  3 in total

1.  Diffuse 18F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia.

Authors:  Zhanli Fu; Jin Zhang; Meng Liu; Ziao Li; Qian Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-07       Impact factor: 9.236

Review 2.  Aneurysmal Subarachnoid Hemorrhage.

Authors:  Athanasios K Petridis; Marcel A Kamp; Jan F Cornelius; Thomas Beez; Kerim Beseoglu; Bernd Turowski; Hans-Jakob Steiger
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

3.  Detection of unexpected emergency diseases using FDG-PET/CT in oncology patients.

Authors:  Akira Toriihara; Emi Yamaga; Masashi Nakadate; Jun Oyama; Ukihide Tateishi
Journal:  Jpn J Radiol       Date:  2017-07-03       Impact factor: 2.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.